Onabotulinumtoxina

Summary

Onabotulinumtoxina (CHEMBL1201574) is an approved unknown (ATC M03AX01); indicated across 112 conditions including cerebral palsy and benign essential blepharospasm.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Unknown
• ATC class: M03AX01
• Indications: 112 conditions
• Clinical trials: 155

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201574
Name	Onabotulinumtoxina
Type	Unknown
Max phase	4
ATC	M03AX01

Also known as: Bontoxilysin, Botox/botox cosmetic, Botulin, Botulinum neurotoxin, Botulinum toxin, Onabotulinumtoxina, RTI-150, RTI150, ONABOTULINUMTOXINA

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

112 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
cerebral palsy	3	MONDO:0006497	EFO:1000632
benign essential blepharospasm	3	MONDO:0011728	Orphanet:93955
stroke disorder	3	MONDO:0005098	EFO:0000712
prostatitis	3	MONDO:0005280	EFO:0003830
neuralgia	3	MONDO:0021667	EFO:0005762
overactive bladder	3	MONDO:0006624	EFO:1000781
Raynaud disease	3	MONDO:0008364	EFO:1001145
nervous system disorder	3	MONDO:0005071	EFO:0000618
gastroparesis	3	MONDO:0006769	EFO:1000948
patellofemoral pain syndrome	3	MONDO:0006894	EFO:1001092
trigeminal neuralgia	3	MONDO:0008599	EFO:1001219
epicondylitis	3	MONDO:0001875	EFO:1001896
hemiplegia	3	MONDO:0001170	EFO:0009453
myofascial pain syndrome	3	MONDO:0006862	EFO:1001054
strabismus	3	MONDO:0003432	HP:0000486
severe cutaneous adverse reaction	3	MONDO:0005594	EFO:0006346
scleroderma	3	MONDO:0019340	EFO:1001993
esotropia	3	MONDO:0004896	HP:0000565
hyperreflexia	3	MONDO:0007774	HP:0001347
migraine disorder	3	MONDO:0005277	MONDO:0005277
multiple sclerosis	3	MONDO:0005301	MONDO:0005301
bruxism	3	MONDO:0002443	MONDO:0002443
obesity disorder	2	MONDO:0011122	EFO:0001073
benign prostatic hyperplasia	2	MONDO:0010811	EFO:0000284
acne	2	MONDO:0011438	EFO:0003894
morbid obesity	2	MONDO:0005139	EFO:0001074
gastric neoplasm	2	MONDO:0021085	EFO:0003897
carpal tunnel syndrome	2	MONDO:0007275	EFO:0004143
muscle tissue disorder	2	MONDO:0003939	EFO:0002970
atrial fibrillation	2	MONDO:0004981	EFO:0000275
carcinoma of esophagus	2	MONDO:0019086	EFO:0002916
essential tremor	2	MONDO:0003233	EFO:0003108
sleep apnea syndrome	2	MONDO:0005296	EFO:0003877
atrial flutter	2	MONDO:0005310	EFO:0003911
androgenetic alopecia	2	MONDO:0005339	EFO:0004191
erectile dysfunction	2	MONDO:0005362	EFO:0004234
thoracic outlet syndrome	2	MONDO:0005979	EFO:0007507
rectal cancer	2	MONDO:0006519	EFO:1000657
burning mouth syndrome	2	MONDO:0006687	EFO:1000850
rotator cuff syndrome	2	MONDO:0007028	EFO:1001250
disease of the tendon	2	MONDO:0100010	EFO:1001434
spinal cord injury	2	MONDO:0043797	EFO:1001919
dementia	2	MONDO:0001627	HP:0000726
interstitial cystitis	2	MONDO:0018301	EFO:0008507
headache disorder	2	MONDO:0021146	EFO:0009550
neuroma	2	MONDO:0002173	EFO:0009619
arthropathy	2	MONDO:0006816	EFO:1000999
plantar fasciitis	2	MONDO:0004833	EFO:1001909
rhinitis	2	MONDO:0003014	EFO:0008521
nasal cavity polyp	2	MONDO:0006314	EFO:1000391
lacrimal apparatus disorder	2	MONDO:0001854	HP:0009926
major depressive disorder	2	MONDO:0002009	MONDO:0002009
compartment syndrome	2	MONDO:0004001	MONDO:0004001
brain injury	2	MONDO:0043510	MONDO:0043510
ulcer disease	2	MONDO:0043839	MONDO:0043839
depressive disorder	2	MONDO:0002050	MONDO:0002050
exocrine pancreatic carcinoma	2	MONDO:0005192	EFO:0002618
scoliosis	2	MONDO:0005392	EFO:0004273
osteoarthritis	2	MONDO:0005178	MONDO:0005178
Parkinson disease	2	MONDO:0005180	MONDO:0005180
temporomandibular joint disorder	2	MONDO:0005473	EFO:0005279
premature ejaculation	2	MONDO:0001780	EFO:0803321
chronic obstructive pulmonary disease	2	MONDO:0005002	EFO:0000341
leiomyoma	2	MONDO:0001572	MONDO:0001572
epidermolysis bullosa simplex	2	MONDO:0017610	MONDO:0017610
injury	1	MONDO:0021178	EFO:0000546
restless legs syndrome	1	MONDO:0005391	EFO:0004270
ventricular tachycardia	1	MONDO:0005477	EFO:0005306
atrophic rhinitis	1	MONDO:0005659	EFO:0007159
dry eye syndrome	1	MONDO:0006733	EFO:1000906
psoriasis	1	MONDO:0005083	EFO:1001494
osteoarthritis, knee	1	MONDO:0005416	EFO:0004616
gingival overgrowth	1	MONDO:0002507	MONDO:0002507
keloid	1	MONDO:0005348	EFO:0004212
spasmodic dystonia	1	MONDO:0000485	MONDO:0000485
skin disorder	1	MONDO:0005093	EFO:0000701
bursitis	0	MONDO:0002471	MONDO:0002471

35 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 155.

Phase distribution

Phase	Trials
PHASE4	41
PHASE3	33
Not specified	30
PHASE2	28
PHASE1	11
PHASE2/PHASE3	7
EARLY_PHASE1	3
PHASE1/PHASE2	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04240535	PHASE4	NOT_YET_RECRUITING	Evaluation of the Safety and Efficacy of OnabotulinumtoxinA to the Depressor Anguli Oris
NCT04305743	PHASE4	RECRUITING	Post-procedural Pain Associated With 5 Versus 20 Intravesical Injections of Onabotulinumtoxin A
NCT04829565	PHASE4	ACTIVE_NOT_RECRUITING	Assessment of Pain After Intra-articular Botulinum Toxin Injections in Carpometacarpal Osteoarthritis of the Thumb
NCT05125029	PHASE4	RECRUITING	Botulinum Toxin in Raynaud’s Phenomenon
NCT05806164	PHASE4	RECRUITING	Beta-Agonist Versus OnabotulinumtoxinA Trial for Urgency Urinary Incontinence
NCT06216886	PHASE4	RECRUITING	OnabotulinumtoxinA for Trigeminal Neuralgia
NCT07082972	PHASE4	RECRUITING	EMG-Based Evaluation of Occlusal Splint and Masseter Botox Effects on Head and Neck Muscles
NCT07220382	PHASE4	RECRUITING	Preoperative BOTOX® Injection for Large Ventral Hernia Repair
NCT07303582	PHASE4	RECRUITING	Individualised Cryoneurolysis to Treat Pain in the Context of Spasticity in the Upper and Lower Extremities
NCT00119886	PHASE4	UNKNOWN	Botox on Vulvar Vestibulitis
NCT00208091	PHASE4	COMPLETED	Quantifying Musical Performance After Treatment With Myobloc in Musician’s Dystonia
NCT01032954	PHASE4	COMPLETED	Safety and Efficacy of the Full Face Applications of Variable Doses of a Commercial Botulinum Toxin Type a (Dysport®)
NCT01071096	PHASE4	COMPLETED	Calcitonin Gene-related Peptide Levels in Chronic Migraine
NCT01269801	PHASE4	COMPLETED	Study of BOTOX and JUVEDERM for Treatment of Moderate to Severe Facial Wrinkles and Folds
NCT01516892	PHASE4	COMPLETED	A Long-term Efficacy, Safety, and Tolerability Study of BOTOX® in Patients With Chronic Migraine
NCT01700387	PHASE4	COMPLETED	A Study to Evaluate the Tolerability of Botox and Topiramate or Botox and Placebo and Effect on Cognitive Efficiency
NCT01732809	PHASE4	COMPLETED	Fields Of Effects Of Two Commercial Preparations Of Botulinum Toxin Type A At Equal Labeled Unit Doses
NCT01777620	PHASE4	COMPLETED	A Study of Subject Satisfaction With BOTOX® Cosmetic Treatment in Facial Rhytides
NCT01833130	PHASE4	COMPLETED	Use of a Treatment Benefit Questionnaire in Patients With Chronic Migraine Treated With OnabotulinumtoxinA (BOTOX®)
NCT01945489	PHASE4	COMPLETED	OnabotulinumtoxinA (BOTOX®) Treatment for Urinary Incontinence in Patients With Overactive Bladder
NCT02037425	PHASE4	COMPLETED	Duration of Benefit for OnabotulinumtoxinA in Treatment of Chronic Migraine
NCT02096081	PHASE4	COMPLETED	The Treatment of Glabellar Frown Lines
NCT02111369	PHASE4	COMPLETED	Propranolol and Botulinum Toxin for Essential Vocal Tremor
NCT02176356	PHASE4	COMPLETED	Patient Satisfaction Study of Combined Facial Treatment With BOTOX® Cosmetic, JUVÉDERM® and LATISSE® (HARMONY Study)
NCT02191579	PHASE4	COMPLETED	Efficacy and Safety Study of BOTOX® Compared to Topiramate for the Prevention of Chronic Migraine in Adults
NCT02361749	PHASE4	UNKNOWN	Botulinum Toxin Injection Versus Anal Myectomy in Management of Idiopathic Constipation
NCT02472210	PHASE4	UNKNOWN	The Use of Botox in Advanced Parkinson’s Patients Experiencing Pain
NCT02786550	PHASE4	UNKNOWN	Botulinum Toxin to Improve Lower Blepharoplasty Scar
NCT03044080	PHASE4	COMPLETED	Effects of Botulinum Neurotoxin Type A (BoNT/A) Free of Complexing Proteins in the Spastic Equinovarus Foot
NCT03052764	PHASE4	COMPLETED	Evaluation of an Alternative Injection Paradigm for OnabotulinumtoxinA (BOTOX®) in the Treatment of Overactive Bladder in Patients With Urinary Incontinence
NCT03373162	PHASE4	COMPLETED	Functional Effects of Botox on the Brain Using MRS and fMRI
NCT03523091	PHASE4	TERMINATED	OnabotulinumtoxinA Bladder Injection Study
NCT04124939	PHASE4	COMPLETED	Is 10 Injections of Bladder Botox Less Painful Than 20 Injections?
NCT04807920	PHASE4	UNKNOWN	BOTOX® at the Time of Prolapse Surgery for OAB
NCT05157295	PHASE4	UNKNOWN	Comparing Number of Injection Sites of In-office Intravesical Onabotulinumtoxin A Treatments for Overactive Bladder: A Randomized Controlled Trial
NCT05308979	PHASE4	COMPLETED	Intradetrusor Botulinum Toxin A for OAB Via 1 Versus 10 Injections: A Randomized Clinical Trial
NCT05605756	PHASE4	TERMINATED	BOTOX Effects on Seizure Severity and Susceptibility
NCT05615987	PHASE4	UNKNOWN	Comparison of Botulinum Toxin Injection Techniques in Spasticity
NCT06080438	PHASE4	TERMINATED	Effect of Topical Botulinum Toxin Eyedrop on Palpebral Fissure
NCT06583343	PHASE4	COMPLETED	Effect of Botulinum Toxin on Selective Motor Control and Pain in Diplegic Cerebral Palsy

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).